• Explore /
  • Poster
  • / A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.

Abstract Poster

Authors

null

Helena Alexandra Yu

Memorial Sloan Kettering Cancer Center, New York, NY

Helena Alexandra Yu , Rachel Kim , Alex Makhnin , Linda Su Hyun Ahn , Ai Ni , Sara A. Hayes , Robert J. Young , Gregory J. Riely , Mark G. Kris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02803203

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9086)

DOI

10.1200/JCO.2019.37.15_suppl.9086

Abstract #

9086

Poster Bd #

409

Abstract Disclosures

Similar Posters

First Author: Helena Alexandra Yu

First Author: Collin M. Blakely

Poster

2018 ASCO Annual Meeting

Tumor mutation burden and efficacy of targeted therapy in patients with <em>EGFR</em> mutant lung cancers.

Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.

First Author: Michael David Offin

First Author: Shen Zhao